Why is Megestrol acetate (mega‑e) used for heavy menstrual bleeding?

Why Megestrol Acetate is Used for Heavy Menstrual Bleeding

Megestrol acetate (a progestin) is used for heavy menstrual bleeding primarily because it causes endometrial atrophy and suppresses endometrial proliferation, resulting in marked reduction of menstrual blood loss—particularly effective when endometrial thickness is >11mm, where it can reduce bleeding by approximately 95%. 1

Mechanism of Action

Megestrol acetate works through several pathways to control heavy menstrual bleeding:

• Direct endometrial effect: The progestin acts locally on the endometrium to thin the lining and reduce blood loss 1
• Hormonal modulation: It inhibits pituitary gonadotropin production, decreasing estrogen secretion and preventing excessive endometrial proliferation 2
• Receptor-mediated action: The drug modifies steroid hormone action by interacting with progesterone receptors in the endometrium 2

Clinical Evidence for Efficacy

The most compelling evidence comes from treatment protocols based on endometrial thickness:

• In patients with thick endometrium (>11mm): Megestrol decreased bleeding from a mean of 54 days to 3 days (P < 0.001), representing the most dramatic reduction among all treatment options 1
• Associated pathology: 52% of patients treated with megestrol in this thickness category had underlying endometrial hyperplasia, making it both therapeutic and diagnostic 1
• Long-term safety: Continuous megestrol acetate (40mg daily) for 9-104 months achieved >90% complete remission in postmenopausal women with endometrial hyperplasia without adverse effects 3

Specific Clinical Contexts

High-Dose Emergency Use

In hemodynamically unstable women with uncontrolled bleeding, high-dose oral or injectable progestin-only medications (including megestrol) may be considered for short-term management 4. This is particularly relevant when:

• Bleeding saturates a large pad or tampon hourly for ≥4 hours 4
• Standard hormonal therapies are contraindicated (e.g., in cardiovascular disease) 4
• NSAIDs and tranexamic acid must be avoided due to thrombotic risk 4

Specialized Populations

In patients with hematologic malignancies undergoing intensive chemotherapy, megestrol (as medroxyprogesterone, a related progestin) is used for menstrual suppression, with 25% of patients with breakthrough bleeding requiring initiation or dose escalation 5.

Important Clinical Caveats

Critical pitfall: The FDA-approved indication for megestrol acetate is palliative treatment of advanced breast or endometrial carcinoma—NOT primary treatment of heavy menstrual bleeding 2. Its use for dysfunctional uterine bleeding represents off-label prescribing, though supported by clinical evidence 1.

Endometrial assessment is mandatory: Before initiating megestrol for heavy bleeding with thick endometrium, endometrial biopsy should be performed to rule out hyperplasia or malignancy 1. This is non-negotiable given the 52% rate of hyperplasia found in one study 1.

Comparison to other progestins: While cyclic oral progestin treatment generally reduces bleeding by 87% 4, megestrol appears particularly effective for cases with significant endometrial thickness where other treatments may fail 1.

Practical Prescribing Approach

When considering megestrol for heavy menstrual bleeding:

1. Measure endometrial thickness via transvaginal ultrasound 1
2. If >11mm: Perform endometrial biopsy before treatment 1
3. Dosing: 40mg daily continuously has been validated for long-term use 3
4. Monitor response: Bleeding should decrease substantially within the first treatment cycle 1
5. Reassess: If no improvement, investigate structural causes or consider alternative therapies 4

The drug's effectiveness stems from its potent progestational effects on the endometrium, making it particularly valuable when standard combined hormonal contraceptives or lower-dose progestins have failed, or when endometrial hyperplasia is present or suspected 1, 3.